Researchers surveyed 385 women younger than 40 years with advanced breast cancer to gather insights about the challenges ...

AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a ...

The latest investment brings the British pharma’s total investment at the site in Qingdao to $886 million. AstraZeneca ...

Precision oncology is tailoring treatments based on molecular profiles, while new surgical and radiotherapy methods boost recovery. Despite challenges like late diagnosis and high treatment costs, ...

Merck & Co. began Tuesday with back-to-back deals, revealing separate agreements to pay $150 million upfront for full control of an early-phase asset and pocket $700 million to support an expansive ...

The "Breast Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. The ...

"ESMO 2025: AstraZeneca and Daiichi Sankyo establish Enhertu in early breast cancer" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

The multicentre, randomised trial was conducted in China, but Sichuan-Kelun and Merck & Co will commercialise sac-TMT in other markets.

Opportunities in the lung cancer antibody drug conjugates market include developing specific, low-toxicity therapies using ADCs, capitalizing on technology platforms like DXd, leveraging collaboration ...

Pregnancy and breastfeeding leave behind long-lived CD8+ T cells that can persist for decades, providing lasting immune surveillance in breast tissue.

Daiichi Sankyo (TSE:4568) posted 11.8% earnings growth over the last twelve months, trailing its 32.7% average from the past five years. Net profit margin edged down to 14.1% from 14.2% a year ago.

Throughout November, LUNGevity is shining a light on the progress being made, and the work still ahead, to change the future of lung cancer WASHINGTON, ...